**OriGene Technologies, Inc.**
9620 Medical Center Drive, Ste 200
Rockville, MD 20850, US
Phone: +1-888-267-4436
https://www.origene.com
techsupport@origene.com
EU: info-de@origene.com
CN: techsupport@origene.cn

# Product datasheet for TL517117V

## Senp2 Mouse shRNA Lentiviral Particle (Locus ID 75826)

### Product data:

| | |
|---|---|
| **Product Type:** | shRNA Lentiviral Particles |
| **Product Name:** | Senp2 Mouse shRNA Lentiviral Particle (Locus ID 75826) |
| **Locus ID:** | 75826 |
| **Synonyms:** | 2310007L05Rik; 4930538C18Rik; AI646780; AW554757; mKIAA1331; Smt3ip2; SuPr-1 |
| **Vector:** | pGFP-C-shLenti (TR30023) |
| **Format:** | Lentiviral particles |
| **Components:** | Senp2 - Mouse shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml. |
| **RefSeq:** | BC031652, NM_029457, NR_027488, NM_001357424, NM_029457.1, NM_029457.2, NM_029457.3, BC040805, BC042514 |
| **UniProt ID:** | Q91ZX6 |
| **Summary:** | Protease that catalyzes two essential functions in the SUMO pathway. The first is the hydrolysis of an alpha-linked peptide bond at the C-terminal end of the small ubiquitin-like modifier (SUMO) propeptides, SUMO1, SUMO2 and SUMO3 leading to the mature form of the proteins. The second is the deconjugation of SUMO1, SUMO2 and SUMO3 from targeted proteins, by cleaving an epsilon-linked peptide bond between the C-terminal glycine of the mature SUMO and the lysine epsilon-amino group of the target protein. May down-regulate CTNNB1 levels and thereby modulate the Wnt pathway. Deconjugates SUMO2 from MTA1 (By similarity). Plays a dynamic role in adipogenesis by desumoylating and promoting the stabilization of CEBPB (PubMed:20194620). Isoform 3 activates transcription. [UniProtKB/Swiss-Prot Function] |
| **shRNA Design:** | These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service. |

View online »

This product is to be used for laboratory only. Not for diagnostic or therapeutic use.
©2022 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US

**Performance Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).

This product is to be used for laboratory only. Not for diagnostic or therapeutic use.
©2022 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US